Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET

By Negrier S.   Jäger E.   Porta C.   McDermott D.   Moore M.   Bellmunt J.   Anderson S.   Cihon F.   Lewis J.   Escudier B.   Bukowski R.  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 899-906

Humana Press, Inc

Access to resources Recommend Favorite

Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma

By                

Molecular and Clinical Oncology, Vol. 3, Iss. 4, 2015-01 ,pp. : 793-796

Science Publishers

Access to resources Recommend Favorite

A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma

By                    

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1099-1102

Science Publishers

Access to resources Recommend Favorite

Long-term results and prognostic factors in patients with stage III–IVA squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy from a single institution study

By Kudaka Wataru   Nagai Yutaka   Toita Takafumi   Inamine Morihiko   Asato Kozue   Nakamoto Tomoko   Wakayama Akihiko   Ooyama Takuma   Tokura Akemi   Murayama Sadayuki   Aoki Yoichi  

International Journal of Clinical Oncology, Vol. 18, Iss. 5, 2013-10 ,pp. : 916-921

Springer Publishing Company

Access to resources Recommend Favorite

An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma

By Pawinski A.   van Oosterom A.T.   de Wit R.   Fossa S.   Croles J.   Svedberg A.   Lentz M.A.   de Mulder P.H.M.  

European Journal of Cancer, Vol. 33, Iss. 3, 1997-03 ,pp. : 496-499

Elsevier

Access to resources Recommend Favorite